Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Stock Has Consensus Price Target of $36.00 According to Analysts

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $36.00.

LKFT has been the topic of a number of recent analyst reports. Raymond James Financial restated a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Thursday, November 12th. TD Cowen began coverage on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Friday, November 13th. They issued a “strong-buy” rating for the company. Royal Bank Of Canada raised shares of Lakefront Biotherapeutics American Depositary Shares from a “sector perform” rating to an “outperform” rating and lifted their target price for the company from $26.00 to $45.00 in a research note on Wednesday, September 23rd. Weiss Ratings raised Lakefront Biotherapeutics American Depositary Shares from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, October 2nd. Finally, UBS Group raised shares of Lakefront Biotherapeutics American Depositary Shares to a “buy” rating in a research report on Wednesday, September 23rd.

Get Our Latest Analysis on LKFT

Institutional Trading of Lakefront Biotherapeutics American Depositary Shares

Institutional investors have recently made changes to their positions in the business. Alps Advisors Inc. acquired a new position in Lakefront Biotherapeutics American Depositary Shares in the third quarter valued at about $2,617,000. Marshall Wace LLP bought a new stake in Lakefront Biotherapeutics American Depositary Shares during the third quarter worth about $2,326,000. Goldman Sachs Group Inc. bought a new stake in Lakefront Biotherapeutics American Depositary Shares during the third quarter worth about $4,166,000. American Century Companies Inc. acquired a new stake in shares of Lakefront Biotherapeutics American Depositary Shares during the third quarter worth approximately $1,227,000. Finally, Commonwealth Equity Services LLC acquired a new stake in shares of Lakefront Biotherapeutics American Depositary Shares during the third quarter worth approximately $279,000. 32.46% of the stock is currently owned by institutional investors and hedge funds.

Lakefront Biotherapeutics American Depositary Shares Stock Performance

Shares of LKFT stock opened at $33.27 on Thursday. The stock has a market capitalization of $2.19 billion, a price-to-earnings ratio of -23.60 and a beta of 0.22. Lakefront Biotherapeutics American Depositary Shares has a one year low of $25.68 and a one year high of $36.24. The company’s 50-day simple moving average is $31.01 and its 200-day simple moving average is $29.93.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT – Get Free Report) last issued its earnings results on Wednesday, November 11th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter. The business had revenue of $7.87 million for the quarter. As a group, research analysts forecast that Lakefront Biotherapeutics American Depositary Shares will post 0.09 EPS for the current year.

Lakefront Biotherapeutics American Depositary Shares declared that its board has approved a stock repurchase plan on Monday, November 16th that permits the company to repurchase $54.95 million in outstanding shares. This repurchase authorization permits the biotechnology company to reacquire up to 2.5% of its stock through open market purchases. Share repurchase plans are typically an indication that the company’s management believes its stock is undervalued.

Lakefront Biotherapeutics American Depositary Shares Company Profile

(Get Free Report)

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.

Further Reading

Analyst Recommendations for Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT)

Receive News & Ratings for Lakefront Biotherapeutics American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakefront Biotherapeutics American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.